Publication Name	World Journal of Hepatology
Manuscript ID	11818
Country	Germany

Received	2014-06-06 08:45
Peer-Review Started	2014-06-08 17:49
First Decision by Editorial Office Director
Return for Revision	2014-07-17 22:31
Revised	2014-07-29 05:34
Publication Fee Transferred
Second Decision by Editor	2014-09-10 13:30
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2014-09-10 13:54
Articles in Press	2014-09-10 13:54
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-10-27 15:04
Publish the Manuscript Online	2014-11-05 09:07

ISSN	1948-5182 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Meta-Analysis
Article Title	Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis
Manuscript Source	Unsolicited Manuscript
All Author List	Nicolae-Catalin Mechie, Christian Röver, Silke Cameron and Ahmad Amanzada
Funding Agency and Grant Number
Corresponding Author	Dr. med. Ahmad Amanzada, MD, Division of Gastroenterology and Endocrinology, University Medical Center Goettingen, Georg-August-University, Robert-Koch-Straße 40, 37075 Goettingen, Germany. ahmad.amanzada@med.uni-goettingen.de
Key Words	Hepatitis C virus; Direct antiviral agents; Interleukin 28B; Sustained virological response; Meta-analysis
Core Tip	Hepatitis C is a world health problem and represents a dynamic field of research for new therapeutic options. Recently direct antiviral agents such as protease inhibitors have been developed which, in addition to pegylated interferon-α and Ribavirin, obtain higher sustained virological response (SVR) rates. Of note, costs are higher and side effects are more common. The data regarding the predictive value of Interleukin 28B (IL-28B) are controversial. This meta-analysis was conducted on 2707 patients treated with different protease inhibitors. Its aim was to clarify the predictive value of IL-28B on SVR in protease inhibitor-based triple-therapy, allowing the possibility of personalized treatment.
Publish Date	2014-11-05 09:07
Citation	Mechie NC, Röver C, Cameron S, Amanzada A. Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis. World J Hepatol 2014; 6(10): 759-765
URL	http://www.wjgnet.com/1948-5182/full/v6/i10/759.htm
DOI	http://dx.doi.org/10.4254/wjh.v6.i10.759

Full Article (PDF)	WJH-6-759.pdf
Full Article (Word)	WJH-6-759.doc
Manuscript File	11818-Review.docx
Answering Reviewers	11818-Answering reviewers.pdf
Biostatistics Review Certificate	Biostatistician_Review_Report_20140606000010.docx
Copyright License Agreement	11818-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	11818-Language certificate.pdf
Peer-review Report	11818-Peer review(s).pdf
Scientific Misconduct Check	11818-CrossCheck.jpg
Scientific Editor Work List	11818-Scientific editor work list.pdf